Wed, December 19, 2018
Tue, December 18, 2018
Mon, December 17, 2018
Fri, December 14, 2018
Thu, December 13, 2018
Wed, December 12, 2018
Tue, December 11, 2018
Mon, December 10, 2018
Fri, December 7, 2018
Thu, December 6, 2018
Wed, December 5, 2018
Tue, December 4, 2018
Mon, December 3, 2018
Fri, November 30, 2018
Thu, November 29, 2018
Wed, November 28, 2018
Tue, November 27, 2018
Mon, November 26, 2018
Fri, November 23, 2018
Wed, November 21, 2018
Tue, November 20, 2018
Mon, November 19, 2018
Fri, November 16, 2018

Charles Duncan Upgraded (VNDA) to Buy and Held Target at $43 on, Dec 4th, 2018


//stocks-investing.news-articles.net/content/201 .. o-buy-and-held-target-at-43-on-dec-4th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Upgraded "Vanda Pharmaceuticals Inc." (VNDA) to Buy and Held Target at $43 on, Dec 4th, 2018.

Charles has made no other calls on VNDA in the last 4 months.



There are 3 other peers that have a rating on VNDA. Out of the 3 peers that are also analyzing VNDA, 0 agree with Charles's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Charles


  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $26 on, Thursday, November 8th, 2018
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $31 on, Tuesday, October 16th, 2018
  • Derek Archila of "Oppenheimer" Maintained at Buy with Increased Target to $29 on, Friday, September 21st, 2018

Publication Contributing Sources